Glenview Capital Management Portfolio holdings
Top Buys
| 1 |
Alight
ALIT
|
+$104M |
| 2 |
Centene
CNC
|
+$80.3M |
| 3 |
GTM
ZoomInfo Technologies
GTM
|
+$64.7M |
| 4 |
DNB
Dun & Bradstreet
DNB
|
+$62.6M |
| 5 |
Myriad Genetics
MYGN
|
+$53.4M |
Top Sells
| 1 |
Corteva
CTVA
|
+$188M |
| 2 |
Cigna
CI
|
+$134M |
| 3 |
Marvell Technology
MRVL
|
+$84M |
| 4 |
DXC Technology
DXC
|
+$69.3M |
| 5 |
McKesson
MCK
|
+$64.6M |
Sector Composition
| 1 | Healthcare | 47.33% |
| 2 | Technology | 18.91% |
| 3 | Industrials | 14.66% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Materials | 4.72% |
Similar funds
Glenview Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Glenview Capital Management held 51 positions worth $3.96B, down 23% from $5.17B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Glenview Capital Management withdrew a net $814M in Q4 2024, closing 15 positions and reducing 15 holdings. Its most notable exit was Marvell Technology, an estimated $84M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 43% a quarter earlier, followed by Technology and Industrials.
Against the trend, Glenview Capital Management opened a new position in Centene worth $78M.
- Glenview Capital Management's largest Q4 2024 buy was Centene: 1,287,341 shares worth $78M.
- Glenview Capital Management added most to Alight in Q4 2024, an estimated $104M increase.
- Glenview Capital Management's biggest Q4 2024 reduction was Corteva, cutting an estimated $188M.
- Glenview Capital Management fully exited Marvell Technology in Q4 2024, selling an estimated $84M.
- Glenview Capital Management's ten largest holdings make up 65% of its $3.96B portfolio in Q4 2024.
- Glenview Capital Management opened 5 new positions and closed 15 in Q4 2024.
- Glenview Capital Management's portfolio value fell 23% quarter-over-quarter to $3.96B.
Based on Glenview Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.